Glyxambi Amputation Attorneys
Parker Waichman LLP is reviewing claims that sodium-glucose cotransporter inhibitors-2 (SGLT2) like Glyxambi have resulted in people living with Type-2 diabetes losing a lower extremity such as a toe, partial foot, foot, or amputation below the knee due to infection caused by SGLT2 usage. Glyxambi, whose generic name is empagliflozin/linagliptin, is produced by Boehringer Ingelheim. Boehringer Ingelheim is a significant drug manufacturer based in Germany but does a considerable amount of business in North America, including the United States with its co-venture Eli Lilly. If your physician prescribed Glyxambi, you should be gravely concerned about pain and infection in your feet and legs. Ignoring these symptoms could lead to the necessity of having your toe, foot, or lower leg amputated.
Parker Waichman LLP Represents Individuals Who Sustained a Leg, Foot or Toes Amputation After Taking Empagliflozin/Linagliptin (Glyxambi)
Parker Waichman LLP is a national firm based in New York whose attorneys are aggressive advocates for their clients who were injured through no fault of their own. Parker Waichman LLP proudly states that its attorneys have recovered over $2 billion in damages for their clients. A law firm cannot create such a tremendous record of success without first having the skill, knowledge, determination, and resources to accomplish the task. So, if you or a loved one has had a limb amputated or suffered another injury or illness such as diabetic acidosis, or kidney failure from taking Glyxambi, then you should contact Parker Waichman LLP to learn more about your rights and how we can recover financial compensation for your losses.
What is Glyxambi?
Glyxambi is a drug designed to lower blood sugar levels in people who have Type 2 diabetes. The primary component of the medication is empagliflozin. Empagliflozin is a medication that falls into the class of medicines known as sodium-glucose cotransporter inhibitors 2 or SGLT2. This drug lowers blood sugar when taken daily. The U.S. Food and Drug Administration (FDA) approved empagliflozin for consumer use in 2014. The brand name of the single therapy drug of empagliflozin is Jardiance.
Glyxambi differs from Jardiance in an important. Glyxambi is a combination of empagliflozin and linagliptin. The FDA approved linagliptin for consumer consumption in 2011 to combat Type 2 diabetes. Together, the drugs offer a compelling alternative to traditional Type 2 diabetes treatments to help remove glucose from the bloodstream when the insulin naturally made by the pancreas can no longer complete that task sufficiently.
Known Side Effects of Empagliflozin/Linagliptin (Glyxambi) SGLT2 Inhibitors
Every medication has potential side effects. The makers of Glyxambi identified several to the FDA upon their trials. Boehringer found that taking Glyxambi could increase the possibility that the user could suffer from pancreatitis. Pancreatitis is an inflammation of the pancreas which can sometimes be fatal. Consequently, the patient must stop taking Glyxambi immediately. Additionally, Boehringer noted to the FDA that low blood pressure, or hypotension, and renal failure or decreased kidney function could also occur when taking Glyxambi,
Possible Unknown Side Effects Empagliflozin/Linagliptin (Glyxambi) SGLT2 Inhibitors
SGLT2 inhibitors have been linked to amputations. Jardiance, as a single therapy, was related to two toe amputations. More significantly, however, Invokana, made by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, has been shown to caused numerous amputations of the lower extremities to the extent that the FDA required Janssen to include a “Black Box Warning” in its prescription label. The Black Box Warning is the highest level of warning a pharmaceutical manufacturer must provide its customers as required by the FDA.
At this time, hundreds of lawsuits are pending in courts through the United States seeking damages for plaintiffs who suffered adverse health problems, including amputations, from taking Invokana.
Other critical health problems related to SGLT2 intake are:
- Diabetic ketoacidosis,
- Renal (kidney) failure,
- Severe urinary tract infections, and
- Yeast infections in both men and women.
Why is it, then, that Glyxambi does not warrant the same Black Box Warning as Invokana? Perhaps the FDA is waiting for people to lose more limbs from taking drugs besides Invokana before they make a connection between all Glifloxin-based medications and amputation.
The European medical authorities do not take the same wait-and-see approach to the situation. The European Health Products Regulatory Authority (HPRA) issued a stern warning in April of 2017. The written warning issued by the HPRA announced to all concerned that all SGLT2 drugs, including empagliflozin (two-thirds of the active ingredient in Glyxambi), maintain a heightened risk of amputation to a lower extremity. This makes sense because all SGLT2 drugs work the same way whether the drug is Invokana (canagliflozin), Jardiance/Glyxambi (empagliflozin), or Forxiga/Xigduo (dapagliflozin).
The European warning mentions explicitly losing a toe to one of the SGLT2. But, the HPRA does not rule out that one could lose more than a toe to an infection caused by an SGLT2 drug.
The HPRA required all of the SGLT2 drug manufacturers to include a warning on their packaging that the threat of amputation is real. Also, the HPRA warned patients to seek medical attention if the patients felt increased pain in the foot, ulcers in the foot or lower leg, tenderness, and discoloration of the foot. Those symptoms indicate that a dangerous problem is mounting in the vascular system of the leg and infection might be growing. Patients should also be aware that they must maintain a proper level of hydration and seek preventative foot care treatment to stave off any potential infection.
Contact Parker Waichman LLP Today to Discuss Your Amputation Claim
Our law firm has received numerous awards and accolades for quality legal work. Parker Waichman LLP has also obtained over $2 Billion in recoveries for their clients. Please visit our Client Testimonials and Verdicts and Settlements pages for further information about our happy clients and the successes we had on their behalf.
At Parker Waichman LLP, our drug defect attorneys aggressively pursue justice for our clients who suffered injuries, or even death, from taking their prescribed medication. If you or a family member suffered a severe injury from taking Glyxambi, call Parker Waichman LLP today at 1-800-YOURLAWYER (1-800-968-7529) or use our contact form. You could be eligible to receive substantial financial compensation for your injuries, medical bills, economic losses, and your pain and suffering.
.svg){kind=small}
.avif)
.avif)